Mesenchymal Stromal Cells for the Delivery of Oncolytic Viruses in Gliomas

Overview

Journal Cytotherapy

Publisher Elsevier

Specialties Cell Biology
Pharmacology

Date 2017 Feb 25

PMID 28233640

Citations 28

Authors

Brittany C Parker Kerrigan

Yuzaburo Shimizu

Michael Andreeff

Frederick F Lang

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.

Citing Articles

Mesenchymal Stem-Cell-Derived Exosomes as Novel Drug Carriers in Anti-Cancer Treatment: A Myth or Reality?.

Harrell C, Volarevic A, Djonov V, Volarevic V Cells. 2025; 14(3).

PMID: 39936993 PMC: 11817634. DOI: 10.3390/cells14030202.

Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.

Minev T, Balbuena S, Gill J, Marincola F, Kesari S, Lin F Oncotarget. 2024; 15:793-805.

PMID: 39576660 PMC: 11584032. DOI: 10.18632/oncotarget.28672.

Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma.

Jazowiecka-Rakus J, Pogoda-Mieszczak K, Rahman M, McFadden G, Sochanik A Int J Mol Sci. 2024; 25(20).

PMID: 39457007 PMC: 11508294. DOI: 10.3390/ijms252011225.

Endovascular surgical neuro-oncology: advancing a new subspecialty.

Young C, Kan P, Chen S, Lang F J Neurooncol. 2024; 170(1):31-40.

PMID: 39222190 DOI: 10.1007/s11060-024-04782-4.

Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system.

El-Ayoubi A, Arakelyan A, Klawitter M, Merk L, Hakobyan S, Gonzalez-Menendez I Mol Oncol. 2023; 18(3):528-546.

PMID: 38115217 PMC: 10920084. DOI: 10.1002/1878-0261.13569.

References

Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M . HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 2004; 11(22):1648-58. DOI: 10.1038/sj.gt.3302289. View

Morshed R, Gutova M, Juliano J, Barish M, Hawkins-Daarud A, Oganesyan D . Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Ther. 2014; 22(1):55-61. PMC: 4293243. DOI: 10.1038/cgt.2014.72. View

Liikanen I, Ahtiainen L, Hirvinen M, Bramante S, Cerullo V, Nokisalmi P . Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013; 21(6):1212-23. PMC: 3681222. DOI: 10.1038/mt.2013.51. View

Stoff-Khalili M, Rivera A, Mathis J, Sanjib Banerjee N, Moon A, Hess A . Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007; 105(2):157-67. DOI: 10.1007/s10549-006-9449-8. View

Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L . Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2008; 17(1):183-90. PMC: 2834971. DOI: 10.1038/mt.2008.229. View

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

Konishi A, Sakushima K, Isobe S, Sato D . First Approval of Regenerative Medical Products under the PMD Act in Japan. Cell Stem Cell. 2016; 18(4):434-5. DOI: 10.1016/j.stem.2016.03.011. View

Chaichana K, Pinheiro L, Brem H . Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther Deliv. 2015; 6(3):353-69. PMC: 4696051. DOI: 10.4155/tde.14.114. View

Klopp A, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M . Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res. 2011; 18(3):771-82. PMC: 3481843. DOI: 10.1158/1078-0432.CCR-11-1916. View

10.

Veerapong J, Bickenbach K, Shao M, Smith K, Posner M, Roizman B . Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007; 67(17):8301-6. DOI: 10.1158/0008-5472.CAN-07-1499. View

11.

GEORGIADES J, Zielinski T, CICHOLSKA A, Jordan E . Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk. 1959; 10:49-57. View

12.

Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J . The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002; 9(6):398-406. DOI: 10.1038/sj.gt.3301664. View

13.

Shafren D, Sylvester D, Johansson E, Campbell I, Barry R . Oncolysis of human ovarian cancers by echovirus type 1. Int J Cancer. 2005; 115(2):320-8. DOI: 10.1002/ijc.20866. View

14.

Ahmed A, Tyler M, Thaci B, Alexiades N, Han Y, Ulasov I . A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm. 2011; 8(5):1559-72. PMC: 3185211. DOI: 10.1021/mp200161f. View

15.

van Eekelen M, Sasportas L, Kasmieh R, Yip S, Figueiredo J, Louis D . Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene. 2010; 29(22):3185-95. PMC: 3390229. DOI: 10.1038/onc.2010.75. View

16.

Harlow E, Whyte P, Franza Jr B, Schley C . Association of adenovirus early-region 1A proteins with cellular polypeptides. Mol Cell Biol. 1986; 6(5):1579-89. PMC: 367684. DOI: 10.1128/mcb.6.5.1579-1589.1986. View

17.

Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O . HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31(10):890-6. DOI: 10.1016/s0301-472x(03)00110-3. View

18.

Menon L, Kelly K, Yang H, Kim S, Black P, Carroll R . Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells. 2009; 27(9):2320-30. DOI: 10.1002/stem.136. View

19.

Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H . Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014; 106(6):dju090. DOI: 10.1093/jnci/dju090. View

20.

Freeman A, Zakay-Rones Z, Gomori J, Linetsky E, Rasooly L, Greenbaum E . Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2005; 13(1):221-8. DOI: 10.1016/j.ymthe.2005.08.016. View